NICE recommends sparsentan for IgA nephropathy
27th May 2025 Uncategorised 0First non-immunosuppressive dual-action therapy approved for eligible patients More: NICE recommends sparsentan for IgA nephropathy Source: News
read more
First non-immunosuppressive dual-action therapy approved for eligible patients More: NICE recommends sparsentan for IgA nephropathy Source: News
read more
Company secures regulatory approvals for commercial rollout in UK and US More: Oxford Brain Diagnostics to launch groundbreaking dementia diagnosis technology Source: News
read moreEurope’s Committee for Medicinal Products for Human Use (CHMP) has recommended GSK’s Blenrep for approval for patients with relapsed or refractory multiple myeloma. The nod was one of several decisions made by the committee this week. More: On the comeback
read moreAstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. More: AstraZeneca, Zero Prostate Cancer rev up early detection push at Memorial Day weekend NASCAR races Source: fierce
read moreIn the ASCENT-03 trial, Gilead’s Trodelvy bested chemotherapy at extending the time before disease worsening or death in certain patients with previously untreated metastatic triple-negative breast cancer. The results help pad the case for Trodelvy in first-line breast cancer following
read morePfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. The FDA has granted its first official approval to a blood-based Alzheimer’s disease test in a potential boon to anti-amyloid drugs. Samsung Biologics plans to spin off its biosimilars
read more© 1994 - 2026 B.M. Pharmaceuticals